

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## HANGZHOU TIGERMED CONSULTING CO., LTD.

### 杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

## PRELIMINARY RESULTS FOR THE YEAR OF 2021

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) pursuant to Rules 13.09 and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The financial data of the Company for the year of 2021 as set out in the announcement is only preliminary accounting data that has not been audited by the accounting firm, and may differ from the final data disclosed in the 2021 annual report, so investors should be aware of the investment risks involved.

### I. MAJOR FINANCIAL DATA AND INDICATORS FOR 2021

*Unit: RMB0'000*

<b>Item</b>	<b>Current reporting period</b>	<b>Corresponding period last year</b>	<b>Rate of increase/decrease</b>
Total operating revenue	521,353.81	319,227.85	63.32%
Operating profit	369,650.29	222,231.19	66.34%
Total profit	368,456.58	221,870.74	66.07%
Net profit attributable to shareholders of the Company	287,416.30	174,977.48	64.26%
Net profit attributable to shareholders of the Company after deducting non-recurring gains and losses	123,152.01	70,819.10	73.90%
Basic earnings per share (RMB)	3.31	2.20	50.45%
Weighted average return on net assets	16.75%	18.68%	-1.93%

	<b>End of the current reporting period</b>	<b>Beginning of the current reporting period</b>	<b>Rate of increase/ decrease</b>
Total assets	2,374,117.16	1,950,605.77	21.71%
Owner's equity attributable to shareholders of the Company	1,812,362.61	1,611,856.80	12.44%
Share capital (0'000 shares)	87,243.84	87,248.35	-0.01%
Net assets per share attributable to shareholders of the Company (RMB)	20.77	18.47	12.45%

Notes: ① The data set out in the announcement is from the consolidated statements of the Company;

② The indicators of basic earnings per share, return on net assets and net assets per share are presented based on the data attributable to shareholders of the Company.

## **II. DETAILS OF THE OPERATING RESULTS AND FINANCIAL POSITION**

### **1. Operating results and financial position**

With the joint efforts of the operation and management team and all employees, the Company's main business has remained its upward momentum, and its operating revenue achieved stable and steady growth.

During the Reporting Period, the Company's operating revenue amounted to RMB5,213,538,100, representing an increase of 63.32% over the same period last year; the total profit was RMB3,684,565,800, representing an increase of 66.07% over the same period last year; the net profit attributable to shareholders of the Company was RMB2,874,163,000, representing an increase of 64.26% over the same period last year.

At the end of the Reporting Period, the Company's total assets was RMB23,741,171,600, representing an increase of 21.71% over the same period last year; the owner's equity attributable to shareholders of the Company was RMB18,123,626,100, representing an increase of 12.44% over the same period last year.

### **2. Non-recurring gains and losses**

During the Reporting Period, the non-recurring gains and losses attributable to shareholders of the Company amounted to RMB1,642,642,900, which was mainly due to the Company's investment into companies that related to the its main business such as biopharmaceuticals and medical devices, as well as financial assets of the healthcare professional investment funds, gains on fair value changes of financial assets and gains from equity transfer received by the Company in accordance with the New Financial Instruments Standards.

## **III. EXPLANATION OF THE DIFFERENCE WITH THE PREVIOUS INDICATIVE RESULTS**

There is no material difference between the operating results disclosed in this preliminary results announcement and the indicative results disclosed in the announcement of "preliminary results for the year of 2021" of the Company dated January 12, 2022.

#### **IV. RISK WARNING**

1. The major financial data set out in this preliminary results announcement is preliminary accounting data that has not been audited by the accounting firm. The specific financial data shall be disclosed in detail in the Company's annual report of 2021.
2. As of the date of this announcement, the board of directors of the Company has not conducted any discussion on the profit distribution for the year of 2021. The information on the Company shall be subject to the information published by the information disclosure media of listed companies on the ChiNext Board designated by the CSRC. Investors are advised to make cautious decision and pay attention to the investment risks involved.

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, March 10, 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.*